Denali Therapeutics Inc.

Overview

Denali Therapeutics Inc. is a biopharmaceutical company developing medicines for serious diseases, including neurodegenerative and lysosomal storage disorders. Its mission is to bring biotherapeutics to the whole body, including the brain; its TransportVehicle™ platform is designed to help large therapeutic molecules cross the blood–brain barrier. The company’s portfolio includes enzyme, oligonucleotide, and antibody programs. AVLAYAH™ (tividenofusp alfa-eknm), for Hunter syndrome, became its first commercial product in 2026.[1]+3

Denali is headquartered in South San Francisco, California, with locations in Salt Lake City and Zurich. It reported approximately 503 full-time employees at year-end 2025. For the three months ended June 30, 2026, it reported $3.6 million in product revenue, primarily following AVLAYAH’s approval and U.S. launch.[5]+2 [1]+6

Products & services

Denali’s commercial product is AVLAYAH (tividenofusp alfa-eknm), an enzyme-replacement therapy designed to deliver iduronate 2-sulfatase, including to the brain. It received FDA accelerated approval in March 2026 for neurologic manifestations of Hunter syndrome (MPS II) in presymptomatic or symptomatic pediatric patients weighing at least 5 kg who do not have advanced neurologic impairment. Approval was based on reduced cerebrospinal-fluid heparan sulfate; continued approval is contingent on confirmation of clinical benefit in the COMPASS study.[8][9]

The company’s clinical-stage candidates include zafinofusp alfa (DNL126) for Sanfilippo syndrome type A; DNL593 for GRN-related frontotemporal dementia; DNL952 for Pompe disease; DNL628 and DNL921 for Alzheimer’s disease; DNL151 for Parkinson’s disease; and eclitasertib (SAR443122/DNL758) for ulcerative colitis. The filing lists these programs at phases ranging from Phase 1 to Phase 2/3.[10] Their modalities include enzyme-replacement therapies, a progranulin protein-replacement therapy, an antisense oligonucleotide program, and a small-molecule LRRK2 inhibitor.[11]+4 AVLAYAH generated $3.6 million in product revenue in the second quarter and first six months of 2026; it was the company’s only commercial product, and the filing does not state product revenue as a percentage of total revenue.[6][16] [8]+9

Geographic presence

Denali Therapeutics’ principal operating base is its headquarters at 161 Oyster Point Blvd., South San Francisco, California. The site provides approximately 148,020 sq. ft. of office, research and development, engineering, and laboratory space and houses a large majority of employees. At year-end 2025, the company had approximately 503 full-time employees; those not based at South San Francisco were remote or at its Salt Lake City, Utah, and Zurich, Switzerland, locations. The company does not disclose an employee count by location.[17]+2

Denali’s Salt Lake City facility comprises approximately 60,000 rentable sq. ft. of office, laboratory, and clinical manufacturing space; the company began operating the clinical manufacturing site in early 2025 and opened it in March 2025. Its Zurich location serves as its European headquarters and contains approximately 163 sq. m. of office and administrative space.[20]+3 Commercially, Denali began U.S. distribution of AVLAYAH in April 2026. Its 2026 interim filing attributes product revenue to U.S. sales; the company also reports conducting clinical trials outside the United States but does not identify the countries or provide a country-by-country revenue breakdown.[4]+2 [17]+9

Business segments

Denali Therapeutics reports one operating and reportable segment, Therapeutics, focused on discovering, developing, and commercializing therapeutics. Its programs span areas including Hunter syndrome, Sanfilippo syndrome, FTD-GRN, Pompe disease, Alzheimer’s disease, Parkinson’s disease, and ulcerative colitis; these are programs within the segment, not separately reported segments.[25]+2

Therapeutics represents 100% of the company’s reported segment structure because it is the sole segment. Denali does not disclose separate percentage contributions for individual programs, products, or collaboration activities.[25][28] [25]+3

Company history

Denali Therapeutics was incorporated in 2013 and publicly launched in 2015, founded by Ryan Watts, Alexander Schuth, and Marc Tessier-Lavigne with an announced initial investment of $217 million. In 2016, it filed its first clinical trial application, for a Phase 1 study of a CNS-penetrant RIP1 inhibitor.[29]+2

In 2018, Denali reported dosing patients in a Phase 1b study of its LRRK2 inhibitor DNL201 and announced a strategic collaboration with Takeda. In 2020, it entered a major Parkinson’s disease collaboration with Biogen involving its LRRK2 inhibitors and options on certain TransportVehicle programs; in 2021, Takeda exercised an option to jointly develop and commercialize the PTV:PGRN program. In March 2026, the FDA granted accelerated approval to AVLAYAH (tividenofusp alfa-eknm) for neurologic manifestations of Hunter syndrome in specified pediatric patients, marking Denali’s first product approval.[32]+4 [29]+7

Sources

• Denali Therapeutics Inc. — Full financial report (2025 Y)
  15 citations

  [1][2][5][17][18][19][20][21][22][23][24][25][26][27][28]
• Denali Therapeutics Inc. — Full financial report (2026 Q 2)
  12 citations

  [3][4][6][8][9][10][11][12][13][14][15][16]
• www.denalitherapeutics.com[7]
• www.sec.gov[29]
• investors.denalitherapeutics.com[30]
• investors.denalitherapeutics.com[31]
• investors.denalitherapeutics.com[32]
• www.takeda.com[33]
• investors.biogen.com[34]
• www.sec.gov[35]
• investors.denalitherapeutics.com[36]